文献速递糖尿病

质子泵抑制剂、肾病与心血管疾病在2型糖尿病中的关系:Fremantle糖尿病研究

Proton Pump Inhibitors, Nephropathy, and Cardiovascular Disease in Type 2 Diabetes: The Fremantle Diabetes Study.
PubMed 文献 · J Clin Endocrinol Metab · 2017-01-01

基于Fremantle糖尿病研究II期,将接受稳定肾素-血管紧张素系统阻断治疗的2型糖尿病患者分为持续未用PPI组、全程使用PPI组、新启用PPI组和停用PPI组,评估PPI使用对肾病和心血管疾病风险的影响。结果显示PPI使用与尿白蛋白/肌酐比值变化无显著关联,但新启用PPI与eGFR下降和5年CVD风险增加相关。

要点

  • 新启用PPI组eGFR下降幅度大于未使用组,校正后平均差为-2.7 mL/min/1.73 m2。
  • 新启用PPI组5年CVD风险增加幅度大于未使用组,校正后平均差为1.7%。
  • 各组间尿白蛋白/肌酐比值变化无统计学显著差异(方差分析P=0.36)。

核心结论

  • PPI使用与尿白蛋白/肌酐比值持续不良影响无关,但新启用PPI与肾病恶化和5年CVD风险增加相关,在2型糖尿病中具有潜在临床意义。

研究设计与样本

  • 纵向观察性研究,纳入Fremantle糖尿病研究II期中接受稳定肾素-血管紧张素系统阻断治疗的2型糖尿病患者,分为未使用PPI组(n=686)、全程使用PPI组(n=174)、新启用PPI组(n=109)和停用PPI组(n=67)。

主要发现

  • 各组间尿白蛋白/肌酐比值变化无统计学显著差异(方差分析P=0.36)。
  • eGFR变化各组间不同(方差分析P=0.002),新启用PPI组下降幅度大于未使用组,校正后平均差(95%CI)为-2.7(-4.5至-0.8)mL/min/1.73 m2,P=0.005。
  • 5年CVD风险变化呈相似模式(方差分析P<0.001),新启用PPI组增加幅度大于未使用组,校正后平均差(95%CI)为1.7%(0.6%至2.8%),P=0.002。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: There is emerging evidence of various adverse effects of chronic proton pump inhibitor (PPI) therapy. OBJECTIVE: To assess the impact of PPI use on nephropathy and cardiovascular disease (CVD) risk in type 2 diabetes. DESIGN: Longitudinal observational study. SETTING: Urban-dwelling community. PATIENTS: Patients with type 2 diabetes from the Fremantle Diabetes Study Phase II and on stable renin-angiotensin system blocking therapy were divided into those remaining untreated with a PPI (group 1, n = 686), on PPI therapy throughout (group 2, n = 174), and commencing (group 3, n = 109) or discontinuing regular PPI therapy (group 4, n = 67) during the 2 years between assessments. MAIN OUTCOME MEASURES: Changes (Δ) in urinary albumin/creatinine ratio (uACR), estimated glomerular filtration rate (eGFR), and predicted 5-year CVD risk. RESULTS: There were no statistically significant differences in ΔuACR between groups [analysis of variance (ANOVA), P = 0.36], but ΔeGFR was different (ANOVA, P = 0.002), with group 3 exhibiting a greater reduction than group 1 [adjusted mean difference (95% confidence interval), -2.7 (-4.5 to -0.8) mL/min/1.73 m2; P = 0.005]. The Δ5-year CVD risk showed a similar pattern (ANOVA, P < 0.001), with group 3 having a greater increase than group 1 [adjusted mean difference (95% confidence interval), 1.7% (0.6% to 2.8%); P = 0.002]. CONCLUSIONS: Although PPI use was not associated with a sustained adverse effect on uACR, the association between PPI initiation and both worsening nephropathy and increasing 5-year CVD risk has potential clinical implications in type 2 diabetes.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Davis TME, Drinkwater J, Davis WA, et al. Proton Pump Inhibitors, Nephropathy, and Cardiovascular Disease in Type 2 Diabetes: The Fremantle Diabetes Study. J Clin Endocrinol Metab. 2017. PMID: 28591820. doi:10.1210/jc.2017-00354

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。